Gibson Dunn Advises Concentra Biosciences on Acquisition of iTeos Therapeutics, Inc.
Firm News | July 21, 2025
Gibson Dunn is representing Concentra Biosciences, an affiliate of Tang Capital Management, on its acquisition of iTeos Therapeutics, Inc. (Nasdaq: ITOS), a biotechnology company that is pioneering the discovery and development of highly differentiated immuno-oncology therapeutics for patients.
Gibson Dunn regularly advises life sciences companies and investors on mergers and acquisitions in the biotechnology and immuno-oncology sectors.
The Gibson Dunn corporate team includes Ryan Murr and Evan Shepherd.